Fig. 5From: Development of a human immuno-oncology therapeutic agent targeting HER2: targeted delivery of granzyme BPharmacokinetic clearance of GrB-Fc-4D5 after IV administration in BALB/c mice. 200 μg of GrB-Fc-4D5 were injected IV into BALB/c mice. Groups of mice (3 mice/group) were sacrificed at various time point after injection. The concentration of fusion protein in plasma was assessed by ELISA according to the protocol in material and method, and the mean blood concentration to time profile of GrB-Fc-4D5 was generated using a least squares nonlinear regressionBack to article page